Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

SELL
$14.09 - $19.87 $265,061 - $373,794
-18,812 Reduced 10.71%
156,835 $2.49 Million
Q2 2023

Aug 02, 2023

BUY
$3.75 - $20.05 $658,676 - $3.52 Million
175,647 New
175,647 $3.31 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track State Of New Jersey Common Pension Fund D Portfolio

Follow State Of New Jersey Common Pension Fund D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

News

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.